Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1757MR)

This product GTTS-WQ1757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2774MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ15695MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ10431MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ2135MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ13171MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ13478MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ10858MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ12535MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW